Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93

Click to increase image sizeClick to decrease image size

Note

Transparency

Declaration of funding

This letter has no funding to declare.

Declaration of financial/other interests

MB, CE, and CB are employees of Amgen, Inc. MB and CE are stockholders in Amgen, Inc. JC is a consultant for Amgen, Inc. and is the recipient of research funding from the Institute for Clinical and Economic Review (ICER). JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

Medical writing support was provided by Matthew Gitlin (BluePath Solutions).

Notes

1 2012 cost information from Tai et al.¹⁵ was inflated to 2017 $US using information from the Bureau of Labor Statistics [BLS] Consumer Price Index [CPI] for Medical Care using quarterly values for Q1 2012 to Q1 2017, resulting in an inflation factor of 1.15511).